Plant ID: NPO28912
Plant Latin Name: Astragalus gummifer
Taxonomy Genus: Astragalus
Taxonomy Family: Fabaceae
NCBI TaxonomyDB:
339493
Plant-of-the-World-Online:
477705-1
Adaptogen; Antitumor; Demulcent
Turkey; Syrian Arab Republic; Iraq; India
GPR35; | |
NPSR1; | |
CDC25B; | |
RECQL; TDP1; BLM; GLO1; HPGD; AKR1B10; ALOX12; HSD17B1; AKR1B1; HSD17B10; NOX4; APEX1; POLB; | |
ACHE; | |
TOP2A; | |
TEK; MET; INSR; AXL; SRC; FLT3; CDK1; EGFR; PIM1; AURKB; NUAK1; KDR; IGF1R; CSNK2A1; | |
CA12; CA7; CA4; | |
RORC; | |
PPARA; | |
ESR2; ESR1; | |
NR1H4; | |
KDM4E; | |
F10; F2; | |
BACE1; | |
MMP12; | |
HIF1A; | |
FUT7; | |
SLC22A6; | |
SMAD3; LMNA; FABP5; HSPA1A; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.088E-08 | 4.084E-06 | AXL, EGFR, F10, INSR, MET, NOX4, SRC, TEK |
MF | GO:0005488; binding | GO:0005524; ATP binding | 6.747E-08 | 1.814E-05 | AURKB, AXL, BLM, CDK1, CSNK2A1, EGFR, FLT3, HSPA1A, IGF1R, INSR, KDR, MET, NUAK1, PIM1, RECQL, SRC, TEK, TOP2A |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.599E-07 | 3.627E-05 | AKR1B1, APEX1, AURKB, BLM, CDC25B, CDK1, CSNK2A1, ESR1, ESR2, FABP5, HIF1A, HPGD, HSPA1A, L3MBTL1, LMNA, NR1H4, NUAK1, PIM1, POLB, PPARA, RECQL, RORC, SMAD3, SRC, TOP2A |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 2.176E-07 | 4.738E-05 | EGFR, IGF1R, INSR, KDR, SRC |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 3.331E-07 | 6.843E-05 | BLM, CA12, CA4, CA7, ESR1, ESR2, GLO1, L3MBTL1, MMP12, NR1H4, PPARA, RORC, SMAD3 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 6.250E-07 | 1.106E-04 | ESR1, ESR2, NR1H4, PIM1, PPARA, RORC, SRC |
BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 6.624E-07 | 1.127E-04 | CYP1A1, HIF1A, LMNA, NOX4, PPARA, SMAD3, SRC, TEK |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 8.188E-07 | 1.351E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
MF | Unclassified; | GO:0004872; receptor activity | 8.170E-07 | 1.351E-04 | AXL, EGFR, ESR1, ESR2, F2, FLT3, GPR35, HPGD, IGF1R, INSR, KDR, MET, NPSR1, NR1H4, PPARA, RORC, TEK |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 1.324E-06 | 2.017E-04 | AXL, CSNK2A1, EGFR, ESR1, PPARA, RORC, SRC, TOP2A |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.813E-06 | 2.685E-04 | EGFR, INSR, KDR |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 1.831E-06 | 2.694E-04 | ESR1, ESR2, NR1H4, PPARA, RORC, SRC |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.462E-06 | 3.330E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3 |
MF | GO:0005488; binding | GO:0042562; hormone binding | 4.287E-06 | 5.396E-04 | ACHE, EGFR, HSD17B1, IGF1R, INSR |
MF | GO:0005488; binding | GO:0005496; steroid binding | 4.542E-06 | 5.587E-04 | ESR1, ESR2, HSD17B1, NR1H4, RORC |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 6.095E-06 | 7.253E-04 | CDK1, ESR1, ESR2, NR1H4, PPARA, RORC |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 6.177E-06 | 7.310E-04 | AKR1B1, AKR1B10, CYP1A1, CYP1B1, ESR1, HSD17B1, NR1H4 |
BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 6.684E-06 | 7.784E-04 | AXL, HIF1A, HSPA1A, MMP12 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 7.961E-06 | 8.935E-04 | APEX1, POLB |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 7.961E-06 | 8.935E-04 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 9.701E-06 | 1.046E-03 | CA12, CA4, CA7 |
MF | Unclassified; | GO:0032403; protein complex binding | 1.221E-05 | 1.255E-03 | ACHE, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP12, PPARA, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.801E-05 | 1.720E-03 | CDK1, EGFR, IGF1R, INSR |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.872E-05 | 1.757E-03 | BACE1, EGFR, INSR, KDR, SLC22A6, SRC, TEK |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.880E-05 | 1.757E-03 | F2, NR1H4, PPARA, SMAD3, TEK |
MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 2.218E-05 | 1.988E-03 | AKR1B1, AKR1B10, HPGD, HSD17B1, HSD17B10 |
BP | GO:0008152; metabolic process | GO:0045893; positive regulation of transcription, DNA-templated | 3.018E-05 | 2.537E-03 | BLM, EGFR, ESR1, ESR2, HIF1A, INSR, MET, MMP12, NR1H4, PPARA, RORC, SMAD3, SRC, TOP2A |
BP | GO:0009987; cellular process | GO:0030520; intracellular estrogen receptor signaling pathway | 3.237E-05 | 2.680E-03 | ESR1, ESR2, SRC |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 3.395E-05 | 2.747E-03 | EGFR, IGF1R, INSR, KDR, TEK |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.421E-05 | 2.749E-03 | ACHE, BLM, CSNK2A1, EGFR, ESR1, ESR2, FLT3, HPGD, IGF1R, KDR, L3MBTL1, MET, SLC22A6, SMAD3, TOP2A |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 3.719E-05 | 2.977E-03 | F2, FLT3, KDR, TEK |
BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 3.770E-05 | 3.007E-03 | AKR1B1, AKR1B10, ALOX12, APEX1, CYP1A1, CYP1B1, HPGD, HSD17B1, HSD17B10, KDM4E, NOX4 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.759E-05 | 3.611E-03 | ESR1, ESR2 |
BP | GO:0032502; developmental process | GO:0007568; aging | 4.871E-05 | 3.657E-03 | APEX1, AURKB, CDK1, CYP1A1, NOX4, POLB |
BP | GO:0009987; cellular process | GO:0050714; positive regulation of protein secretion | 5.359E-05 | 3.955E-03 | ACHE, EGFR, HIF1A, MMP12, NR1H4, SRC |
BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 5.903E-05 | 4.270E-03 | ALOX12, CYP1A1, CYP1B1, GLO1, HIF1A, HPGD, NR1H4, PPARA |
BP | GO:0009987; cellular process | GO:0071363; cellular response to growth factor stimulus | 6.750E-05 | 4.696E-03 | EGFR, INSR, KDR, NOX4, SMAD3, SRC |
BP | GO:0009987; cellular process | GO:0046427; positive regulation of JAK-STAT cascade | 6.823E-05 | 4.731E-03 | AKR1B1, CYP1B1, F2, FLT3 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 7.574E-05 | 5.203E-03 | AXL, IGF1R, INSR |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 7.614E-05 | 5.214E-03 | ALOX12, CYP1B1, HIF1A, KDR, TEK |
MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 7.917E-05 | 5.321E-03 | BLM, RECQL |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 8.398E-05 | 5.571E-03 | FLT3, SRC, TEK |
MF | GO:0005488; binding | GO:0003690; double-stranded DNA binding | 1.005E-04 | 6.383E-03 | APEX1, EGFR, ESR1, ESR2, HIF1A, NR1H4, PPARA, RORC, SMAD3, TDP1 |
BP | GO:0065007; biological regulation | GO:0043406; positive regulation of MAP kinase activity | 1.018E-04 | 6.447E-03 | CDK1, EGFR, FLT3, INSR, NOX4, SRC |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.022E-04 | 6.450E-03 | CSNK2A1, HIF1A, KDR |
BP | GO:0008152; metabolic process | GO:1902893; regulation of pri-miRNA transcription from RNA polymerase II promoter | 1.122E-04 | 6.920E-03 | HIF1A, PPARA, SMAD3 |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 1.122E-04 | 6.920E-03 | INSR, PPARA, SRC |
BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 1.185E-04 | 7.250E-03 | ALOX12, HPGD |
BP | GO:0008152; metabolic process | GO:1903580; positive regulation of ATP metabolic process | 1.228E-04 | 7.427E-03 | CDK1, HIF1A, INSR |
BP | GO:0008283; cell proliferation | GO:0050679; positive regulation of epithelial cell proliferation | 1.390E-04 | 8.180E-03 | EGFR, HIF1A, KDR, MMP12, TEK |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 1.428E-04 | 8.356E-03 | AURKB, BLM, CSNK2A1, L3MBTL1, NUAK1 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.459E-04 | 8.502E-03 | CA12, CA4, CA7 |
BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 1.460E-04 | 8.502E-03 | EGFR, ESR1, HIF1A, MET, SMAD3, SRC |
BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 1.656E-04 | 9.369E-03 | EGFR, POLB |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 1.656E-04 | 9.369E-03 | FLT3, KDR |
MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 1.656E-04 | 9.369E-03 | EGFR, ESR1 |
MF | GO:0003824; catalytic activity | GO:0043140; ATP-dependent 3'-5' DNA helicase activity | 1.656E-04 | 9.369E-03 | BLM, RECQL |
BP | GO:0008152; metabolic process | GO:0016101; diterpenoid metabolic process | 1.675E-04 | 9.423E-03 | AKR1B10, CYP1A1, CYP1B1, EGFR |
BP | GO:0051179; localization | GO:0060341; regulation of cellular localization | 1.735E-04 | 9.737E-03 | CDK1, CSNK2A1, EGFR, F2, HIF1A, LMNA, NPSR1, NR1H4, SMAD3, SRC |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 1.742E-04 | 9.753E-03 | CDK1, EGFR, F2, SMAD3 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 1.250E-09 | 1.625E-07 | SMAD3, CSNK2A1, SRC, INSR, MET, EGFR, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 2.518E-07 | 1.636E-05 | HSD17B1, INSR, CYP1A1, CYP1B1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.344E-06 | 5.653E-05 | SRC, KDR, HIF1A, ESR1, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.739E-06 | 5.653E-05 | SRC, INSR, KDR, TEK, MET, EGFR, IGF1R |
09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 6.726E-06 | 1.663E-04 | SMAD3, SRC, KDR, MET, EGFR, HSPA1A, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 7.674E-06 | 1.663E-04 | SRC, ESR1, EGFR, ESR2, HSPA1A |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.315E-06 | 1.730E-04 | INSR, TEK, HIF1A, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 3.646E-05 | 4.740E-04 | INSR, KDR, TEK, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 3.449E-05 | 4.740E-04 | FLT3, MET, HIF1A, EGFR |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.372E-04 | 3.653E-03 | INSR, KDR, TEK, MET, EGFR, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 2.309E-04 | 2.729E-03 | SRC, KDR, MET, EGFR, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 7.513E-04 | 6.104E-03 | SMAD3, FLT3, HIF1A, MET, EGFR, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 4.902E-04 | 4.902E-03 | SMAD3, INSR, EGFR, IGF1R |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 7.281E-04 | 6.104E-03 | INSR, HSPA1A, IGF1R |
09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 8.690E-04 | 6.646E-03 | SRC, MET, EGFR |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.324E-03 | 8.605E-03 | PIM1, CYP1B1, MET, EGFR, CDC25B |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 9.853E-04 | 7.021E-03 | MET, EGFR, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.455E-04 | 5.066E-03 | HSD17B1, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.026E-03 | 7.021E-03 | SRC, ESR1, ESR2 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.302E-05 | 2.116E-04 | CA12, CA4, CA7 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.513E-03 | 9.367E-03 | HPGD, FLT3, MET, IGF1R |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
NA: NA | Haemophilia B | NA | F10; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; F2; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; F2; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; F2; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; EGFR; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
NA: NA | Christmas disease | NA | F10; |
NA: NA | Menopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; F10; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; HIF1A; TEK; EGFR; SRC; F2; CDC25B; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; F2; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; F2; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; F2; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; INSR; EGFR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; F2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; INSR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; SRC; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; SRC; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; F2; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | TEK; SRC; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | TEK; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; HIF1A; TEK; EGFR; SRC; F2; |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | INSR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; TEK; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; INSR; EGFR; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; F2; |
I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; F2; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; F2; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; F2; |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; SRC; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; INSR; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | INSR; AKR1B1; |
I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; INSR; |
I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; SRC; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; INSR; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; SRC; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
NA: NA | GIST | NA | FLT3; |